Center Laboratories : Announcement on the Company's board resolution to increase the investment on Mycenax Biotech Inc

Close

Today's Information

Provided by: Center Laboratories, Inc.
SEQ_NO	1	Date of announcement	2022/07/27	Time of announcement	16:18:12
Subject	Announcement on the Company's board resolution to increase the investment on Mycenax Biotech Inc
Date of events	2022/07/27	To which item it meets	paragraph 24
Statement	1.Name and nature of the underlying security (if preferred shares, the terms and conditions of issuance shall also be indicated, e.g., dividend yield): Mycenax Biotech Inc. issues common shares through private placement 2.Date of occurrence of the event:2022/07/27 3.No., unit price, and monetary amount of the transaction: Volume：8,000,000 shares Unit price：NTD 32.5 per share Total monetary amount：NTD 260,000million 4.Counterparty to the trade and its relationship to the company (if the trading counterparty is a natural person and not a related party of the company, its name is not required to be disclosed): Mycenax Biotech Inc. is one of the Company's portfolio companies, where the Company holds 21.9% shares. 5.Where the counterparty to the trade is a related party, an announcement shall also be made of the reason for choosing the related party as trading counterparty and the identity of the previous owner, including its relationship with the company and the trading counterparty, the price of the ownership transfer, and date of transfer: For a long-term investment. 6.Where the owner of the underlying securities within the past five years has been a related party of the company, an announcement shall also include the dates and prices of acquisition and disposal by the related party and its relationship with the company at the time:NA 7.Matters related to the creditor's rights currently being disposed of (including type of collateral of the disposed creditor's rights; if the creditor's rights are creditor's rights over a related party, the name of the related party and the book amount of such creditor's rights currently being disposed of must also be announced):NA 8.Profit (or loss) from the disposal (not applicable in cases of acquisition of securities) (where originally deferred, the status or recognition shall be stated and explained):NA 9.Terms of delivery or payment (including payment period and monetary amount), restrictive covenants in the contract, and other important stipulations: Pay in full of the subscription amount within the payment deadline. 10.The manner in which the current transaction was decided, the reference basis for the decision on price, and the decision-making unit: Method of the decision: based on the resolutions from the Board of Director's meeting. The decision-making party and references for pricing decision: based on the subscription price determined by Mycenax's board resolution. 11.Net worth per share of company of the underlying securities acquired or disposed of:NT12.56 12.The discrepancy between the reference price of private placement company and the transaction amount per share is 20 percent or more:No 13.Restrictions (e.g., pledges) on cumulative no., amount, and shareholding ratio and rights of the securities being traded (including the current transaction) as of the date of occurrence: The cumulative volume：41,974,314 shares The cumulative amount：NTD1,003,282 in thousands Shareholding ratio：20.46% Any restriction of rights：14,800thousand Pledged Shares and accordance with the relevant regulations and authorities for private placement. 14.Privately placed securities (including the current transaction) as a percentage of total assets of the company and shareholder's equity of the parent company on the latest financial statements, and the operating capital on the latest financial statements as of the date of occurrence: Proportion accounted to the total assets: 78.55% Proportion of equity attributable to Stockholders of the Company: 100.01% Operating capital: NTD2,613,396 thousand 15.Broker and broker's fee:None 16.Concrete purpose or use of the acquisition or disposition:For a long-term investment 17.Whether the directors expressed any objection to the present transaction:No 18.Whether the trading counterparty is a related party:Yes 19.Date of approval by board of directors:2022/07/27 20.Recognition date by supervisors or approval date by audit committee:NA 21.Whether the CPA issued an opinion on the unreasonableness of the current transaction:NA 22.Name of the CPA firm:NA 23.Name of the CPA:NA 24.License no. of the CPA:NA 25.Any other matters that need to be specified:None.